228 related articles for article (PubMed ID: 24939104)
21. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives as mTOR inhibitors.
Zhu W; Sun C; Xu S; Wu C; Wu J; Xu M; Zhao H; Chen L; Zeng W; Zheng P
Bioorg Med Chem; 2014 Dec; 22(24):6746-54. PubMed ID: 25468038
[TBL] [Abstract][Full Text] [Related]
22. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel pazopanib derivatives as antitumor agents.
Qi H; Chen L; Liu B; Wang X; Long L; Liu D
Bioorg Med Chem Lett; 2014 Feb; 24(4):1108-10. PubMed ID: 24456902
[TBL] [Abstract][Full Text] [Related]
24. 4-Substituted-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives: design, synthesis, antitumor and EGFR tyrosine kinase inhibitory activity.
Abbas SE; Aly EI; Awadallah FM; Mahmoud WR
Chem Biol Drug Des; 2015 May; 85(5):608-22. PubMed ID: 25318985
[TBL] [Abstract][Full Text] [Related]
25. Pyrazolo[1,5-a]pyrimidine based Trk inhibitors: Design, synthesis, biological activity evaluation.
Zhang Y; Liu Y; Zhou Y; Zhang Q; Han T; Tang C; Fan W
Bioorg Med Chem Lett; 2021 Jan; 31():127712. PubMed ID: 33246108
[TBL] [Abstract][Full Text] [Related]
26. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors.
Dehbi O; Tikad A; Bourg S; Bonnet P; Lozach O; Meijer L; Aadil M; Akssira M; Guillaumet G; Routier S
Eur J Med Chem; 2014 Jun; 80():352-63. PubMed ID: 24793883
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis and Biological Evaluation of Novel Urea and Thiourea Bearing thieno[3,2-d]-pyrimidines as PI3 Kinase Inhibitors.
Bodige S; Ravula P; Gulipalli KC; Endoori S; Chandra JNNS; Cherukumalli PKR; Vanaja G R ; Seelam N
Anticancer Agents Med Chem; 2018; 18(6):891-902. PubMed ID: 29424321
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
31. Entry into a new class of protein kinase inhibitors by pseudo ring design.
Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J
Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of 2-amino-4-(7-azaindol-3-yl)pyrimidines as cyclin dependent kinase 1 (CDK1) inhibitors.
Huang S; Li R; Connolly PJ; Emanuel S; Middleton SA
Bioorg Med Chem Lett; 2006 Sep; 16(18):4818-21. PubMed ID: 16870444
[TBL] [Abstract][Full Text] [Related]
33. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors.
Chikhale R; Thorat S; Choudhary RK; Gadewal N; Khedekar P
Bioorg Chem; 2018 Apr; 77():84-100. PubMed ID: 29342447
[TBL] [Abstract][Full Text] [Related]
35. Single step synthesis of new fused pyrimidine derivatives and their evaluation as potent Aurora-A kinase inhibitors.
Shaaban MR; Saleh TS; Mayhoub AS; Farag AM
Eur J Med Chem; 2011 Sep; 46(9):3690-5. PubMed ID: 21664013
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Schenone S; Brullo C; Bruno O; Bondavalli F; Mosti L; Maga G; Crespan E; Carraro F; Manetti F; Tintori C; Botta M
Eur J Med Chem; 2008 Dec; 43(12):2665-76. PubMed ID: 18342402
[TBL] [Abstract][Full Text] [Related]
37. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
[TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines.
Ostrynska OV; Balanda AO; Bdzhola VG; Golub AG; Kotey IM; Kukharenko OP; Gryshchenko AA; Briukhovetska NV; Yarmoluk SM
Eur J Med Chem; 2016 Jun; 115():148-60. PubMed ID: 27017545
[TBL] [Abstract][Full Text] [Related]
39. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]